BioGaia AB - Company Profile
Powered by 
All the sales intelligence you need on BioGaia AB in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how BioGaia AB fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with BioGaia AB.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
BioGaia AB (BioGaia) is a healthcare company that develops, markets and sells probiotic products. The company sells its probiotic food supplements and health products in various dosage forms, including drops, lozenges, chewable tablets, oral rehydration solutions (ORS), capsules, powders and ointments. BioGaia's products are based on various strains of Lactobacillus reuteri, its patented lactic acid bacterium. The company's major product areas include child and adult gut health, and, immune, oral, skin and bone health. The company sells its products through its distributors in the APAC (Asia and the Pacific), EMEA (Europe, Middle East, and Africa) and the Americas (South America, Canada and the US). BioGaia is headquartered in Stockholm, Sweden.
Headquarters
Sweden
Address
Kungsbroplan 3, Stockholm, 11227
Website
https://www.biogaiagroup.com/
Telephone
46 8 55529300
No of Employees
242
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BIOG B (STO)
Revenue (2025)
$145.5M
8.1%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
-5.3%
(2025 vs 2024)
Market Cap*
$1.2B
Net Profit Margin (2025)
XYZ
-12.4%
(2025 vs 2024)
* As of and is in US$
BioGaia AB premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Gut Health: Colic, constipation, irritable bowel syndrome (IBS), acute diarrhea, antibiotic-associated side effects such as diarrhea, treatment of H. pylori infection. | BioGaia |
| Protectis ORS | |
| Protectis MINIPACK | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In February, the company renewed its distribution agreement with Ewopharma. |
| 2025 | New Products/Services | In September, the company launched BioGaia Prodentis FRESH BREATH lozenges, a microbiome-friendly dental probiotic designed to promote fresh breath and support oral health, expanding its specialized oral care product portfolio. |
| 2024 | Acquisitions/Mergers/Takeovers | In November, the company sold a 4.9% stake to Anatom Holding AG, an investment firm. |
Competitor Comparison
| Key Parameters | BioGaia AB | Novonesis AS | Probi AB | Bifodan A/S | Essum AB |
|---|---|---|---|---|---|
| Headquarters | Sweden | Denmark | Sweden | Denmark | Sweden |
| City | Stockholm | Bagsvaerd | Lund | Hundested | Umea |
| State/Province | - | - | - | - | Vasterbotten |
| No. of Employees | 242 | 11,641 | 157 | - | - |
| Entity Type | Public | Public | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Mauricio Graber | Chairman | Executive Board | 2025 | 63 |
| Theresa Agnew | Chief Executive Officer; President | Senior Management | 2023 | 60 |
| Alexander Kotsinas | Executive Vice President; Chief Financial Officer | Senior Management | 2019 | 59 |
| Ludvig Milesson | Chief Operating Officer | Senior Management | 2023 | 49 |
| Caroline Mofors | Chief Legal Officer | Senior Management | 2023 | 54 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer